UNIQURE N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.95 USD | +5.77% |
|
+3.99% | -26.88% |
| May. 08 | Mizuho Adjusts uniQure's Price Target to $6 From $7, Keeps Neutral Rating | MT |
| May. 07 | UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 49.47M 53.65M | Sales 2025 * | 87.7M 95.11M | Capitalization | 222M 240M |
|---|---|---|---|---|---|
| Net income 2024 * | -218M -236M | Net income 2025 * | -167M -181M | EV / Sales 2024 * | 3.08 x |
| Net cash position 2024 * | 69.35M 75.21M | Net Debt 2025 * | 9.03M 9.79M | EV / Sales 2025 * | 2.63 x |
| P/E ratio 2024 * |
-1.07
x | P/E ratio 2025 * |
-1.35
x | Employees | 480 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.72% |
More Fundamentals
* Assessed data
More news
Latest transcript on uniQure N.V.
More recommendations
More press releases
| 1 day | +5.77% | ||
| 1 week | +3.99% | ||
| 1 month | +8.32% | ||
| 3 months | -11.45% | ||
| 6 months | -30.67% | ||
| Current year | -26.88% |
1 week
4.52
5.05
1 month
4.525.19
Current year
4.257.12
1 year
4.2520.84
3 years
4.2538.80
5 years
4.2582.49
10 years
4.2582.49
| Managers | Title | Age | Since |
|---|---|---|---|
Matt Kapusta
CEO | Chief Executive Officer | 51 | 14-12-31 |
Christian Klemt
DFI | Director of Finance/CFO | 51 | 14-12-31 |
Pierre Caloz
COO | Chief Operating Officer | 52 | 21-05-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leonard Post
BRD | Director/Board Member | 72 | 20-06-16 |
Jack Kaye
BRD | Director/Board Member | 80 | 16-06-14 |
| Director/Board Member | 61 | 17-09-13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.96% | 11 M€ | -6.03% | - | |
| 0.76% | 14 M€ | -5.07% | ||
| 0.48% | 28 M€ | -1.00% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 4.95 | +5.77% | 525,857 |
| 24-05-30 | 4.68 | +0.65% | 501,712 |
| 24-05-29 | 4.65 | -1.48% | 822,703 |
| 24-05-28 | 4.72 | -0.84% | 517,544 |
| 24-05-24 | 4.76 | -.--% | 225,844 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Companyâs lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntingtonâs disease is in Phase I/II clinical study.
Calendar
2024-06-18
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
4.564
EUR
Average target price
17.09
EUR
Spread / Average Target
+274.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.88% | 240M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- QURE Stock
